Results 181 to 190 of about 56,276 (247)

Rituximab for a rare pediatric case of concurrent thyroid eye disease and myasthenia gravis. [PDF]

Ther Adv Endocrinol Metab
Zhang H, Lu T, Li Y, Guan H, Bahn RS, Zhou H.   +5 more
europepmc   +1 more source

Roadmap to Nanomedical Applications: Nanotoxicology and In Vitro Guidelines for Lanthanide‐Doped Luminescence Nanothermometers

Advanced NanoBiomed Research, Volume 5, Issue 6, June 2025.
Lanthanide‐based luminescence nanothermometry holds multifaceted potential for nanomedical applications, yet despite significant research advances, clinical translation of the engineered nanomaterials is still controversial and widely disputed. This is related to crucial nanotoxicological aspects that must be addressed at the preclinical level ...
Simona Premcheska, Andre G. Skirtach, Anna M. Kaczmarek   +2 more
wiley   +1 more source

Satralizumab Ameliorates Refractory Central Neuropathic Pain and Painful Tonic Spasms in Neuromyelitis Optica Spectrum Disorder: A Case Report. [PDF]

Cureus
Matsuo J, Nakahara K, Hara Y, Ueda M.
europepmc   +1 more source

Rational Design of Single‐Domain Antibodies Targeting the Central Nervous System Neurite Outgrowth Inhibitor Nogo‐A

Applied Research, Volume 4, Issue 3, June 2025.
The development of a nanobody for Nogo‐A, a potent neurite outgrowth inhibitor crucial in multiple sclerosis, is reported using a rational design approach. The nanobody targets the Nogo‐A ectodomain at the S1PR2 receptor‐binding region with submicromolar KD.
Vaidehi Roy Chowdhury, Alexander Röntgen, Matthew Greenig, Yanira Méndez Gómez, Sebastian P. Spiegel, Magdalena Nowinska, Aubin Ramon, Pietro Sormanni, Andrew Chan, Michele Vendruscolo   +9 more
wiley   +1 more source

A novel agent targeting APRIL: A new hope for elderly patients of IgA nephropathy. [PDF]

Aging Med (Milton)
Liu X, Zuo L.
europepmc   +1 more source

Outcome of Patients With Lupus Nephritis Treated With an Anti‐CD40 Monoclonal Antibody According to Kidney Biopsy Features

Arthritis &Rheumatology, Volume 77, Issue 6, Page 696-704, June 2025.
Objective A phase 2 trial tested different doses of the anti‐CD40 monoclonal antibody BI 655064 as an add‐on therapy to the standard of care in patients with class III or IV lupus nephritis (LN) with active disease. A post hoc analysis showed a potential benefit of the higher tested doses (180 and 240 mg) versus a low dose (120 mg) or placebo.
Martina Uzzo, Helmut Schumacher, Juergen Steffgen, Simone Deutschel, David Jayne, Ingeborg Bajema   +5 more
wiley   +1 more source

Repulsive Guidance Molecule-A as a Therapeutic Target Across Neurological Disorders: An Update. [PDF]

Int J Mol Sci
Tseriotis VS, Liampas A, Lazaridou IZ, Karachrysafi S, Vavougios GD, Hadjigeorgiou GM, Papamitsou T, Kouvelas D, Arnaoutoglou M, Pourzitaki C, Mavridis T.   +10 more
europepmc   +1 more source

Multiple Use of Regenerated Depth Filters in Antibody Purification Processes

Biotechnology and Bioengineering, Volume 122, Issue 6, Page 1366-1375, June 2025.
ABSTRACT During the manufacturing of therapeutic antibodies, disposable depth filters are used after affinity chromatography to remove haze and process‐related impurities such as host cell proteins (HCP) and DNA known as critical quality attributes.
Bernhard Spensberger, Ferdinand Stueckler, Marc Pompiati, Christoph Feistl, Thorsten Lemm, Roberto Falkenstein   +5 more
wiley   +1 more source

Research trends in anti-rabies virus monoclonal antibody: A bibliometric analysis. [PDF]

Hum Vaccin Immunother
Liu C, Lv X, Liu S, Chen Q, Zhu Z, Yu R, Yin W, Wang C.   +7 more
europepmc   +1 more source

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application

Chronic Diseases and Translational Medicine, Volume 11, Issue 2, Page 105-116, June 2025.
Donanemab, approved by the U.S. FDA in July 2024, targets amyloid plaques in the brain to treat Alzheimer's disease in patients with mild cognitive impairment or mild dementia. ABSTRACT Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD).
Nandhini Jayaprakash, Karthikeyan Elumalai   +1 more
wiley   +1 more source